Ascentage Pharma Group International (36X) Stock Overview
A clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
36X Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Ascentage Pharma Group International Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$3.50 |
| 52 Week High | HK$10.00 |
| 52 Week Low | HK$0.84 |
| Beta | 0.65 |
| 1 Month Change | -12.94% |
| 3 Month Change | -28.57% |
| 1 Year Change | -54.55% |
| 3 Year Change | 45.83% |
| 5 Year Change | -28.28% |
| Change since IPO | 1.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| 36X | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.4% | -0.5% | -0.9% |
| 1Y | -54.5% | -3.9% | 1.9% |
Return vs Industry: 36X underperformed the German Biotechs industry which returned -5.1% over the past year.
Return vs Market: 36X underperformed the German Market which returned 3.3% over the past year.
Price Volatility
| 36X volatility | |
|---|---|
| 36X Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in DE Market | 13.4% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 36X's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 36X's weekly volatility has decreased from 84% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 767 | Dajun Yang | www.ascentage.cn |
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin’s lymphoma.
Ascentage Pharma Group International Fundamentals Summary
| 36X fundamental statistics | |
|---|---|
| Market cap | €1.30b |
| Earnings (TTM) | -€160.01m |
| Revenue (TTM) | €73.92m |
Is 36X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 36X income statement (TTM) | |
|---|---|
| Revenue | CN¥574.12m |
| Cost of Revenue | CN¥48.94m |
| Gross Profit | CN¥525.18m |
| Other Expenses | CN¥1.77b |
| Earnings | -CN¥1.24b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.38 |
| Gross Margin | 91.48% |
| Net Profit Margin | -216.47% |
| Debt/Equity Ratio | 146.7% |
How did 36X perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/17 18:30 |
| End of Day Share Price | 2026/06/17 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ascentage Pharma Group International is covered by 25 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yang Huang | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Suranjit Mukherjee | BTIG |